TW201417822A - 用於治療痤瘡的局部用組成物 - Google Patents
用於治療痤瘡的局部用組成物 Download PDFInfo
- Publication number
- TW201417822A TW201417822A TW102133208A TW102133208A TW201417822A TW 201417822 A TW201417822 A TW 201417822A TW 102133208 A TW102133208 A TW 102133208A TW 102133208 A TW102133208 A TW 102133208A TW 201417822 A TW201417822 A TW 201417822A
- Authority
- TW
- Taiwan
- Prior art keywords
- topical formulation
- formulation
- extract
- acne
- topical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 206010000496 acne Diseases 0.000 title claims abstract description 57
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims description 30
- 230000000699 topical effect Effects 0.000 title description 9
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 64
- 238000009472 formulation Methods 0.000 claims abstract description 58
- 239000000284 extract Substances 0.000 claims abstract description 53
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 18
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 18
- 229960003321 baicalin Drugs 0.000 claims abstract description 18
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003951 masoprocol Drugs 0.000 claims abstract description 8
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 7
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 7
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 7
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 240000005250 Chrysanthemum indicum Species 0.000 claims abstract description 5
- 244000234609 Portulaca oleracea Species 0.000 claims abstract description 5
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 5
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims abstract description 4
- 240000001745 Rheum palmatum Species 0.000 claims abstract description 3
- 235000008090 Rheum palmatum Nutrition 0.000 claims abstract description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 56
- 239000006071 cream Substances 0.000 claims description 31
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 28
- 229960004889 salicylic acid Drugs 0.000 claims description 28
- 239000012676 herbal extract Substances 0.000 claims description 23
- 241000208680 Hamamelis mollis Species 0.000 claims description 14
- 244000042664 Matricaria chamomilla Species 0.000 claims description 14
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 14
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 14
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 210000002374 sebum Anatomy 0.000 claims description 12
- 229940118846 witch hazel Drugs 0.000 claims description 12
- 229940064064 purslane extract Drugs 0.000 claims description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- -1 hydroxyphenyl propylamine Hydroxyphenyl propamidobenzoic acid Chemical compound 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 8
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 8
- 206010040880 Skin irritation Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000036556 skin irritation Effects 0.000 claims description 8
- 231100000475 skin irritation Toxicity 0.000 claims description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- 235000012211 aluminium silicate Nutrition 0.000 claims description 7
- 229940036350 bisabolol Drugs 0.000 claims description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002195 synergetic effect Effects 0.000 claims description 7
- 239000011787 zinc oxide Substances 0.000 claims description 7
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 6
- 235000017945 Matricaria Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- CUCUKLJLRRAKFN-UHFFFAOYSA-N 7-Hydroxy-(S)-usnate Chemical compound CC12C(=O)C(C(=O)C)C(=O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O CUCUKLJLRRAKFN-UHFFFAOYSA-N 0.000 claims description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 5
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- 229940004858 usnic acid Drugs 0.000 claims description 5
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 claims description 5
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usninic acid Natural products CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 claims description 5
- 235000014692 zinc oxide Nutrition 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 3
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims description 3
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 3
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 3
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 claims description 3
- 241000208681 Hamamelis virginiana Species 0.000 claims description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 2
- 229940074094 sapindus mukorossi fruit extract Drugs 0.000 claims description 2
- 230000037384 skin absorption Effects 0.000 claims description 2
- 231100000274 skin absorption Toxicity 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 16
- 239000000419 plant extract Substances 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 25
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 15
- 230000003902 lesion Effects 0.000 description 14
- 241000219061 Rheum Species 0.000 description 13
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 206010033733 Papule Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 5
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 239000004342 Benzoyl peroxide Substances 0.000 description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 241000207929 Scutellaria Species 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 229940047169 astragalus root extract Drugs 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 230000037312 oily skin Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000010215 titanium dioxide Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- FPHOEKDYJLXBSV-UHFFFAOYSA-N OC1=C(C(=C(C(=O)O)C=C1)NCCC)C1=CC=CC=C1 Chemical compound OC1=C(C(=C(C(=O)O)C=C1)NCCC)C1=CC=CC=C1 FPHOEKDYJLXBSV-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 235000006029 Prunus persica var nucipersica Nutrition 0.000 description 2
- 244000017714 Prunus persica var. nucipersica Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241001233305 Xanthisma Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical class OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- DLFOKZQWYFNKCL-UHFFFAOYSA-N 2-[3-(4-hydroxyphenyl)propanoylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC(=O)CCC1=CC=C(O)C=C1 DLFOKZQWYFNKCL-UHFFFAOYSA-N 0.000 description 1
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 description 1
- RGMWPKBUUOBFLN-UHFFFAOYSA-N 4-hydroxy-3-phenyl-2-(prop-2-enoylamino)benzoic acid Chemical compound OC1=C(C(=C(C(=O)O)C=C1)NC(C=C)=O)C1=CC=CC=C1 RGMWPKBUUOBFLN-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Chemical class C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 229930190481 Avenanthramide Natural products 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000006555 Chamaerops humilis Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Chemical class O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000580938 Sapindus Species 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 229940116924 hydroxyphenyl propamidobenzoic acid Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- KJWVVSYDYGOFSU-UHFFFAOYSA-N propyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCC KJWVVSYDYGOFSU-UHFFFAOYSA-N 0.000 description 1
- 239000012673 purified plant extract Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Chemical class OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本發明係有關包含植物萃取物，結合額外成分之局部用配方。本發明更有關該配方於治療痤瘡之用途。特別的是，本發明係有關包含馬齒莧(Portulaca oleracea)萃取物、掌葉大黃(Rheum palmatum)萃取物、油菊(Chrysanthemum indicum)萃取物與黃芩(Scutellaria baicalensis)根萃取物，或其活性成分黃芩苷(Baicalin)，以及去甲二氫癒創木酸(nordihydroguaiaretic acid)與齊墩果酸(oleanolic acid)之局部用配方。
Description
本發明係有關包含植物萃取物連同額外之成分之局部用配方。本發明更有關該配方於治療痤瘡之用途。
痤瘡(Acne vulgaris)(囊腫型痤瘡或"痤瘡")為常見之皮膚病，其特徵為皮膚發紅、粉刺(黑頭與白頭)、丘疹(針頭狀)、膿皰(疙瘩)、結節(大型丘疹)與疤痕。痤瘡大多影響皮膚毛囊皮脂腺最密集部位；這些區域包括臉部、胸部上方與背部。嚴重型痤瘡具有發炎性，不過痤瘡也有非發炎形式。此類病變之成因為毛囊皮脂腺單位、毛囊與其相關皮脂腺組成之皮膚結構之改變，以及該變化需要雄性激素刺激。痤瘡最常出現在青春期，且通常延續至成年期。痤瘡被認為是西方國家最普遍皮膚疾病之一。痤瘡於成年人之盛行率為約25%，而有90%青少年於12至24歲期間患有痤瘡。其症狀特徵為臉部、頸部、背部、胸部與肩部常出現腫塊。痤瘡之嚴重程度因人而異，且遺傳因素扮演重要角色。其致病因素包括皮脂分泌、毛囊角化、微生物族群，
以及免疫性與發炎過程。
依據廣泛之理論，痤瘡病變之初步發展階段為角質細胞異常脫落，其阻止正常皮脂排出。青少年體內循環之雄性激素增加，刺激了皮脂產生，導致周圍毛囊腫脹。這些情況之結合，於皮脂腺內產生有利於痤瘡桿菌(Propionibacterium acnes)增生之環境。滋生之痤瘡桿菌會分泌各種炎性分子與趨化因子，其啟動局部發炎反應，並可能同時誘發角質細胞過度增生。然而，證據顯示，發炎情況於病變形成之前出現，且堵塞情況在一定程度上，會受到痤瘡桿菌之發炎影響。
現行之痤瘡病變類型可分為發炎性與非發炎性病變。
非發炎性病變亦稱為粉刺。非發炎性病變為固體小型白色丘疹，一般直徑小於1mm，其含有由皮脂與角化碎片構成之白色碎片核心(封閉性粉刺)，或暗灰色碎片核心，係因暴露於空氣與之後氧化(開放性粉刺)所致。
發炎性病變包括丘疹、膿皰與結節。發炎性病變之範圍可由高溫固化紅斑性丘疹、含化膿性材料之核心膿皰，至較大硬結性病變。後者若其直徑小於5mm，則被界定為結節。
鑑於習知之痤瘡治療之缺點，目前仍需要一種含草藥之局部用組成物，以用於治療。
本發明之實施例係有關包含馬齒莧(Portulaca oleracea)萃取物、掌葉大黃(Rheum palmatum)萃取物、油菊(Chrysanthemum indicum)萃取物與黃芩(Scutellaria baicalensis)根萃取物，或其活性成分黃芩苷(Baicalin)，結合去甲二氫癒創木酸(nordihydroguaiaretic acid)與齊墩果酸(oleanolic acid)之局部用配方。進一步之實施例係有關使用上述配方治療或預防痤瘡。依據一些實施例，該配方進一步包含甘草酸二鉀(dipotassium glycyrrhizate)、洋甘菊(母菊屬)(Chamomilla recutita(matricaria))花萃取物與北美金縷梅(金縷梅)(Hamamelis virginiana(witch hazel))之一或多者。
依據一些實施例，該配方進一步包含水楊酸、尿囊素(allantoin)與沒藥醇(α-bisabolol)之一或多者。依據一些實施例，該配方進一步包含高嶺土(kaolin)、氧化鋅、沙棘油(hippophae rhamnoides oil)、松蘿酸(usnic acid)、羥苯基丙醯胺基苯甲酸(hydroxyphenyl propamidobenzoic acid)、二氧化鈦之一或多者。依據一些實施例，該配方進一步包含咪唑啶基尿素(imidazolidinyl urea)、甲基氯異噻唑啉酮(methylchloroisothiazolinone)與甲基異噻唑啉酮(methylisothiazolinone)之一或多者。
本發明之一些實施例係有關包含馬齒莧萃取物、無患子(Sapindus mukorossi)果萃取物與月桂醇聚醚硫酸銨(ammonium laureth sulfate)、椰油醯胺基丙基甜菜鹼(cocamidopropyl betaine)、椰油醯胺MEA(cocamide MEA)、
椰油醯胺DEA(cocamide DEA)之至少一者之局部用配方。依據一些實施例，上述配方係用於治療或預防痤瘡。
依據一些實施例，該配方提供涵蓋皮脂分泌減少、皮膚油類吸收、抗發炎活性、抗菌活性、傷口癒合特性、抗氧化活性、皮膚刺激減少、配方之皮膚吸收，或其任何結合之協同效用。
本發明之進一步實施例係有關治療痤瘡之方法，其包含以本文詳述之局部用配方，局部施加至有需要之個體。
本發明於此以附圖說明，但僅用於示範。可具體參考詳細之圖示說明，必須強調的是，以範例方式之詳盡描述，目的僅在於說明本發明之較佳實施例，並提供被認為最適用與易於理解之闡述，以呈現本發明之原則與觀點。在此方面，除了本發明所需之基本理解之外，並未試圖以更詳盡方式呈現本發明之構成細節，而用於體現本發明之各種形式之圖示與說明，對於本領域之技術人員而言將是顯而易見。
圖1A、1B、1C與1D為比較結果之圖示說明，其於患有痤瘡之個體中，比較本發明示範性實施例之面霜與先前較差療效之配方之治療功效。特別的是，圖1A與1B圖示說明本發明實施例之面霜之結果，而圖1C與1D圖示說明先前較差療效之配方之結果。
圖2A、2B、2C與2D為比較結果之圖示說明，其
於患有痤瘡之個體中，比較了本發明示範性實施例之遮瑕處理配方，與先前較差療效之配方之治療功效。圖2A與2B圖示說明本發明實施例之遮瑕處理之結果，而圖2C與2D圖示說明先前較差療效之遮瑕處理配方之結果。
圖3係圖示說明以水楊酸單獨，及以水楊酸結合草藥混合物治療後，病患之痤瘡發炎性病變減少。
本發明之一實施例為包含馬齒莧萃取物、掌葉大黃萃取物、油菊萃取物與黃芩根萃取物，或其活性成分黃芩苷，結合去甲二氫癒創木酸與齊墩果酸之局部用配方。本發明之一些實施例係有關使用包含馬齒莧萃取物、掌葉大黃萃取物、油菊萃取物與黃芩根萃取物，或其活性成分黃芩苷，結合去甲二氫癒創木酸與齊墩果酸之局部用配方，治療及/或預防痤瘡。
依據一些實施例，該局部用配方進一步包含一或多個下列試劑：氧化鋅、高嶺土、二氧化鈦、沙棘油、羥苯基丙醯胺基苯甲酸、松蘿酸、甘草酸二鉀、洋甘菊(母菊屬)花萃取物、水楊酸、甘油、北美金縷梅(金縷梅)水、尿囊素、沒藥醇，或其任何之結合物。
依據一些實施例，該局部用配方進一步包含氧化鋅、高嶺土、二氧化鈦、沙棘油、羥苯基丙醯胺基苯甲酸與松蘿酸，或其任何結合物之一或多者。
依據一些實施例，該局部用配方進一步包含甘草
酸二鉀、洋甘菊(母菊屬)花萃取物、水楊酸、甘油、北美金縷梅(金縷梅)水、尿囊素與沒藥醇，或其任何結合物之一或多者。
依據一些實施例，該局部用配方包含馬齒莧萃取物、掌葉大黃萃取物、油菊萃取物與黃芩根萃取物，或其活性成分黃芩苷，結合去甲二氫癒創木酸與齊墩果酸，以及水楊酸、尿囊素、沒藥醇、甘草酸二鉀、洋甘菊(母菊屬)花萃取物與北美金縷梅(金縷梅)之一或多者。依據一些實施例，該局部用配方不含對羥苯甲酸酯(paraben)。依據一些實施例，該配方之pH值為介於約3.5-4.5之間。依據一些實施例，該配方之pH值為介於約3.0-5.0之間。依據一些實施例，該配方之pH值為介於約3.0-5.5之間。在一些實施例中，該配方為面霜形式。
依據一些實施例，該局部用配方包含馬齒莧萃取物、掌葉大黃萃取物、油菊萃取物與黃芩根萃取物，或其活性成分黃芩苷，結合去甲二氫癒創木酸與齊墩果酸。依據一些實施例，該配方進一步包含高嶺土、氧化鋅、二氧化鈦、沙棘油與羥苯基丙醯胺基苯甲酸之一或多者。依據進一步之實施例，該配方進一步包含咪唑啶基尿素、甲基氯異噻唑啉酮與甲基異噻唑啉酮之一或多者。依據一些實施例，該局部用配方不含對羥苯甲酸酯。依據一些實施例，該配方之pH值為介於約7.0-8.0之間。在一些實施例中，該配方為遮瑕處理配方形式。
本發明之一些實施例係有關包含馬齒莧萃取
物、無患子果萃取物與月桂醇聚醚硫酸銨、椰油醯胺基丙基甜菜鹼、椰油醯胺MEA、椰油醯胺DEA之至少一者之局部用配方。本發明之其他實施例係有關使用包含馬齒莧萃取物、無患子果萃取物與月桂醇聚醚硫酸銨、椰油醯胺基丙基甜菜鹼、椰油醯胺MEA、椰油醯胺DEA之至少一者之局部用配方，治療痤瘡。依據一些實施例，該配方不含十二基硫酸鈉(SLS)。依據一些實施例，該配方為潔淨凝膠形式。
依據一些實施例，該局部用配方包括抗發炎成分、抗菌成分、調節皮脂分泌成分、皮膚保濕成分、止痛劑、抗刺激劑、抗氧化劑，及其任何之結合物之一或多者。
依據一些實施例，該局部用配方之活性成分提供協同效用，以治療及/或預防痤瘡。依據進一步之實施例，配方中活性成分之至少一者與其他成分之至少一者之結合物，係提供協同效用，以治療及/或預防痤瘡。協同效用可為直接性，以治療/預防病症、間接性，如藉由增進配方/活性成分之穿透進入皮膚或減少皮膚刺激，或同時為直接性與間接性。
氧化鋅之使用有助於降低皮脂量。高嶺土可用於吸收油性皮膚之過多油脂與滲出液。黃芩苷與掌葉大黃可減少雄性激素受體表達，因此，可用於減少雄性激素媒介之皮脂腺活性刺激，導致皮脂量下降。因此，掌葉大黃與黃芩，或其活性成分黃芩苷，之結合物，連同氧化鋅及/或高嶺土，或任何其他同等成分，可協同地減少皮膚之皮脂
分泌與油吸收。
羥苯基丙醯胺基苯甲酸，一種合成之燕麥蒽醯胺(avenanthramide)，可增進草藥混合物之抗發炎活性。此外，掌葉大黃萃取物亦具有特異於痤瘡之抗發炎活性，係因其抑制細胞介素如IL-1α。因此，依據一些實施例，羥苯基丙醯胺基苯甲酸，或任何同等成分，以及掌葉大黃可協同地增進配方之抗發炎活性。
去甲二氫癒創木酸與齊墩果酸，係藉由抑制5α-還原酶作用，以及控制細菌生長，而減少過度角化(hyperkeratosis)、抑制發炎與減少皮脂分泌。此外，松蘿酸已知具有抗菌活性，而北美金縷梅(金縷梅)水已知具有抗發炎特性。此類成分，或同等物，可以協同方式，結合具有抗發炎活性之草藥萃取物，如馬齒莧萃取物、掌葉大黃萃取物、油菊萃取物與黃芩根萃取物或黃芩苷，以治療痤瘡。當結合調節皮脂分泌之萃取物，如掌葉大黃萃取物及黃芩根萃取物或黃芩苷使用時，亦可協同地治療痤瘡。依據一些實施例，當結合馬齒莧萃取物使用時，上述成分或其同等物可協同地增進對於痤瘡桿菌之抗菌活性。值得注意的是，痤瘡桿菌之減少，與發炎媒介物之減少及痤瘡之臨床上改進有相關性。當結合馬齒莧萃取物與掌葉大黃萃取物使用時，上述成分可進一步協同地增進傷口癒合能力。
沙棘油(沙棘籽油)可作為傷口癒合之用。因此，其結合物，或任何其他之同等成分，結合具有傷口癒合能力之草藥萃取物，如馬齒莧萃取物與掌葉大黃萃取物，可
提供協同效用，以舒緩痤瘡發生與減少疤痕形成。沙棘油與北美金縷梅(金縷梅)水更為已知之抗氧化劑。因此，其結合物，或任何其他之同等成分，可協同地增進草藥萃取物之抗氧化劑活性，其降低了痤瘡之嚴重性與症狀。
洋甘菊(母菊屬)花萃取物具有抗發炎活性，並可減少皮膚刺激。因此，其結合物，或任何其他之同等成分，結合草藥萃取物混合物，可協同地減少痤瘡病患之發炎與皮膚刺激。此外，依據一些實施例，該配方進一步包含水楊酸，其可能會引起皮膚刺激。洋甘菊(母菊屬)花萃取物之添加可同時減少此種皮膚刺激。亦可添加尿囊素與沒藥醇，以減少皮膚刺激，包括加入水楊酸造成之刺激。
依據進一步之實施例，該局部用配方進一步包含水楊酸。依據進一步之實施例，該局部用配方進一步包含至少0.3% w/w水楊酸。依據進一步之實施例，該局部用配方進一步包含至少0.4% w/w水楊酸。依據進一步之實施例，該局部用配方進一步包含至少0.5% w/w水楊酸。依據進一步之實施例，該局部用配方進一步包含約1.0% w/w水楊酸。依據進一步之實施例，該局部用配方進一步包含範圍為0.4-2.5% w/w之水楊酸。依據進一步之實施例，該局部用配方進一步包含範圍為0.5-2.0% w/w之水楊酸。依據進一步之實施例，該局部用配方進一步包含範圍為0.5-1.5% w/w之水楊酸。依據進一步之實施例，該局部用配方進一步包含範圍為0.5-1.0% w/w之水楊酸。依據進一步之實施例，該局部用配方進一步包含範圍為1.25-2% w/w之水楊酸。
依據進一步之實施例，該局部用配方進一步包含過氧化苯。依據進一步之實施例，該局部用配方進一步包含至少1.5% w/w過氧化苯。依據進一步之實施例，該局部用配方進一步包含至少2.0% w/w過氧化苯。依據進一步之實施例，該局部用配方進一步包含至少2.5% w/w過氧化苯。依據進一步之實施例，該局部用配方進一步包含範圍為1.5-12.0% w/w之過氧化苯。依據進一步之實施例，該局部用配方進一步包含範圍為2.0-11.0% w/w之過氧化苯。依據進一步之實施例，該局部用配方進一步包含範圍為2.5-10.0% w/w之過氧化苯。
依據一些實施例，該局部用配方之pH值為介於約3.0-5.0之間。依據進一步之實施例，該局部用配方之pH值為介於約3.5-4.5之間。依據進一步之實施例，該局部用配方之pH值為介於約2.5-6.0之間。依據一些實施例，該局部用配方之pH值為介於約6.0-9.0之間。依據進一步之實施例，該局部用配方之pH值為介於約7.0-8.0之間。依據進一步之實施例，該局部用配方之pH值為介於約6.5-8.5之間。
依據一些實施例，該配方之草藥萃取物之結合濃度為至少0.75%。依據一些實施例，該配方之草藥萃取物之結合濃度為至少0.9%。依據一些實施例，該配方之草藥萃取物之結合濃度為至少1.0%。依據一些實施例，該配方之草藥萃取物之結合濃度為介於約0.8-1.2%之間。依據一些實施例，該配方之草藥萃取物之結合濃度為至少8.0%。依據一些實施例，該配方之草藥萃取物之結合濃度為至少
9.0%。依據一些實施例，該配方之草藥萃取物之結合濃度為至少10.0%。依據一些實施例，該配方之草藥萃取物之結合濃度為介於約9.0-11%之間。
依據一些實施例，該配方之草藥萃取物之每一者之量為約0.3%。依據一些實施例，該配方之草藥萃取物之每一者之量之範圍為約0.25-0.35%。依據一些實施例，該配方之草藥萃取物之每一者之量之範圍為約0.2-0.4%。
依據一些實施例，該配方包含至少0.075%黃芩苷。依據一些實施例，該配方包含至少0.085%黃芩苷。依據一些實施例，該配方包含至少0.095%黃芩苷。依據進一步之實施例，依據進一步之實施例，該面霜配方包含至少0.1%黃芩苷。依據一些實施例，該遮瑕處理配方包含至少1.0%黃芩苷。依據一些實施例，該面霜之草藥萃取物濃度為約1.0-1.6%。依據一些實施例，該遮瑕膏之草藥萃取物濃度為約9.0-11.0%。利用常規方法，本發明之配方可配製成多種製備物，其取決於預期之用途。這些製備物包括但不侷限於，醫療用之局部用皮膚組成物，以及局部用皮膚化妝品組成物。
在醫療用之局部用皮膚組成物與局部用皮膚化妝品組成物方面，可使用凝膠、軟膏、肥皂、面霜與乳液之多種形式。可以任何適用之方式施加配方，亦即，經由手、刮勺、噴霧或墊。
本發明之配方可為面霜、遮瑕處理，或潔淨凝膠形式。本發明之配方可施加至經痤瘡感染之全部皮膚區域，
或局部針對各個瘡。當施加至人體皮膚時，本發明之配方具有高度皮膚相容性與低刺激性。依據一些實施例，該配方係施加至人體並隨後以，如清水洗滌方式，將其移除。
以本發明之局部用組成物作為化妝品組成物使用時，化妝品或皮膚病學上可接受成分，可任擇地以所希望之任意組合併入，並依據本領域之習知技術測定。依據一些實施例，該組成物可包括油類、脂肪、蠟、清潔劑、調和劑、pH值調節劑、防腐劑、溶劑、黏度調節劑、著色劑、香料、染料及其類似物。
該組成物可為水包油、油包水、水包油包水，以及矽膠包水包油乳液、霜劑、軟膏、水性溶液、洗劑、肥皂、糊劑、泡沫劑、乳液、凝膠、油膏、油液、洗液、調理劑或氣霧形式。
依據本發明之一實施例，本發明之組成物係每日投予一次。依據其他實施例，該組成物之投予為每日兩次、每日三次或以上。
依據本發明之一實施例，該組成物為長期投予。
依據本發明之一些實施例，該組成物之投予為約10天或以上、20天、30天、60天、90、120天或以上。
在本發明之一些實施例中，該組成物進一步包含清潔劑或界面活性劑，其典型上為陰離子、陽離子、非離子或兩性界面活性劑。典型之陰離子界面活性劑為羧酸鹽類、磺酸鹽類、硫酸鹽類或磷酸鹽類，如脂肪酸皂類、月桂基硫酸鹽類與月桂基醚硫酸鹽類。陽離子界面活性劑之
範例為衍生自脂肪酸與松香酸之脂族單、二與多胺類、胺氧化物類、乙氧基化烷基胺類與咪唑啉類。非離子界面活性劑之範例為聚氧乙烯界面活性劑、烷基酚乙氧基化物、羧酸酯類，如單與二甘油酯、聚氧乙烯酯類與脂肪酸二乙醇胺縮合物。兩性界面活性劑為那些含有上述陰離子與陽離子基團之結合物者，特別是那些同時含有酸性羧基與鹼性氮基者。典型之兩性界面活性劑為咪唑啉類與甜菜鹼，如月桂酸與肉荳蔻咪唑啉及甜菜鹼，以及醯胺丙基甜菜鹼。
局部用醫藥組成物，亦可包含適用之乳化劑，意指可增進或促進水包油或油包水之混合與懸浮者。本文所使用之乳化劑可由單一乳化劑，或可由非離子、陰離子、陽離子或兩性界面活性劑，或二或多個此類界面活性劑之摻合物組成；用於本文者較佳為非離子與離子乳化劑。此類界面活性劑係描述於“McCutcheon's Detergent and Emulsifiers,”North American Edition,1980 Annual published by the McCutcheon Division,MC Publishing Company,175 Rock Road,Glen Rock,N.J.07452,USA。
CTFA Cosmetic Ingredient Handbook,Second Edition(1992)中，描述了多種皮膚保養產業中常見之非侷限性化妝品成分，其適合本發明組成物使用。這些成分類別之範例包括：研磨劑、吸收劑、美觀成分，如香料、顏料、增色劑/著色劑、精油、皮膚增感劑、收斂劑等(例如，丁香油、薄荷醇、樟腦、桉葉油、丁香酚、乳酸薄荷酯、金縷梅餾出物)、抗痤瘡劑、防結塊劑、消泡劑、抗菌劑(例
如，碘化丙基丁基胺甲酸酯)、抗氧化劑、黏合劑、生物添加劑、緩衝劑、填充劑、熬合劑、化學添加劑、著色劑、化妝品收斂劑、化妝品生物滅除劑、變性劑、藥物收斂劑、外用止痛劑、成膜劑或材料，如聚合物，有助於組成物之成膜特性與持久性(例如，二十碳烯與乙烯基吡咯啶酮之共聚合物)、遮光劑、pH值調節劑、推進劑、還原劑、螯合劑、皮膚調理劑(例如，濕潤劑，包括混雜型與封閉型)、皮膚舒緩劑及/或癒合劑(例如，泛醇及衍生物(例如，乙基泛醇)、蘆薈、泛酸及衍生物、尿囊素、沒藥醇，與甘草酸二鉀)、皮膚治療劑、增稠劑，與維生素，及其衍生物。
可由配方之實施例進行治療或預防之其他皮膚病為例如，不限於，頭皮屑與油性皮膚狀況。
術語“約”意指±10%。術語% w/w，係指特定成分之重量於整體製劑重量中之百分比。
術語“皮膚學上可接受載體”，使用於此，意指相容於皮膚、頭皮、毛髮、指甲及其類似物之載體。
術語“預防”意指確保個體不發生疾病、異常或症狀。在某些情況下，個體可能有發展為疾病之風險，但未被診斷出患有該疾病。在某些情況下，術語"預防"意指預防下一循環之疾病發生。
本文所使用之植物萃取物可由極性溶劑，例如乙基醇(乙醇)、丁基醇(丁醇)、甲醇、水，或丙醇、丙二醇、丁二醇、甘油，純化(亦即，極性萃取物)。本發明之極性萃取物可包含任何百分比之極性溶劑。
或者，植物萃取物可由非極性溶劑，例如但不侷限於異辛烷純化(亦即，非極性萃取物)。本發明之非極性萃取物可包含任何百分比之非極性溶劑。
典型而言，疏水性分子趨向於非極性，因此使用非極性溶劑。親水性分子趨向於極性，並可由水及/或其他極性物質溶解。
活性成分可由萃取物中濃縮出，係使用親和層析法、質量層析法，及其類似方法。
典型而言，本發明之植物萃取物為水性萃取物。欲取得經純化之植物萃取物(例如，植物萃取物之有機鹽類，及/或重金屬，及/或澱粉之含量減少)，水性植物萃取物一般係進一步以樹脂層析法，如巨孔型樹脂或其他層析方法純化。將甘油、丙二醇、丁二醇或丙二醇加入水性萃取物中，以評估萃取物之溶解度、評估其皮膚穿透能力，並進一步保存該萃取物。萃取物亦可包含防腐劑。
因此，依據另一實施例，係提供一種製備含有經濃縮草藥萃取物之組成物之方法，以治療及/或預防痤瘡，該方法包含：(a)將植物置於1-10倍體積之水中，以產生植物萃取物；以及(b)以巨孔型樹脂減少植物萃取物之雜質含量，使植物萃取物之活性成分含量提高。
依據一些實施例，該配方包含任何額外之成分，包括溶劑、潤膚劑、保濕劑、調和劑、黏度劑、皮膚鎮靜劑、乳化劑、pH值調節劑、防腐劑、抗氧化劑、增黏劑、香料、濕潤劑、抗痤瘡劑、穩定劑與界面活性劑。
上述面霜之pH值範圍為介於約3.5-4.5之間。
進行兩種面霜處理之比較。第一種面霜之成分詳述於上表II，而第二種療效較差之面霜詳述於下表VI：
表VI之面霜之pH值範圍為介於約6.0-7.5之間。
以面霜施加至六位年齡28.7±7.7之病患臉部六至七天，其中第一種面霜施加至一半臉上，而第二種面霜施加至另一半臉上。
參與者於受試期結束時填寫評量問卷，其中該問卷涵蓋下列標準：1.產品對於丘疹數量之影響；2.產品對於丘疹嚴重性之影響；3.產品對於油性皮膚之影響；4.產品對於皮膚發紅之影響；5.產品對於黑頭粉刺之影響；6.整體外觀；7.產品之整體評估；以及8.產品質地。
準則1-5可評價為具有：無影響、最小影響或顯著影響；以及準則6-8可評價為：不良、尚可、良好與極佳。
治療研究之結果圖示於圖1A、1B、1C與1D。
圖1A與1C之間，以及圖1B與1D之間的比較顯示，相較於以第二種面霜治療(詳述於表VI且圖示於圖1C與1D)，以第一種面霜治療(詳述於表II且圖示於圖1A與1B)，在所有標準中皆較具有療效與滿意度，但產品對於黑頭粉刺之影響除外，因兩種產品之情況類似。
進行兩種遮瑕處理配方之比較。第一種遮瑕處理配方之成分詳述於上表I，而第二種面霜詳述於下表VII：
表VII所列配方之pH值為介於約6-7之間。
以一天兩次施加遮瑕處理配方至五位年齡44.8±10.3之病患臉部七天，其中第一種面霜施加至一半臉上，而第二種面霜施加至另一半臉上。遮瑕處理配方被視為厚面霜或軟膏。
參與者於受試期結束時填寫評量問卷，其中該問卷涵蓋下列標準：1.產品對於丘疹數量之影響；2.產品對於丘疹嚴重性之影響；3.產品對於皮膚發紅之影響；4.整體外觀；5.產品之整體評估；以及6.產品質地。
標準1-3可評價為具有：無影響、最小影響或顯著影響；以及準則4-6可評價為：不良、尚可、良好與極佳。
治療研究之結果圖示於圖2A、2B、2C與2D。圖2A與2C之間，以及圖2B與2D之間的比較顯示，相較於以第二種面霜治療(詳述於表VII且圖示於圖2C與2D)，以第一種面霜治療(詳述於表I且圖示於圖2A與2B)，在所有標準中皆較具有療效與滿意度，但產品對於皮膚發紅之影響除外，因兩種產品之情況類似。
28位患有痤瘡個體之半邊臉部，以含有草藥混合物+0.5%水楊酸之配方處理12天，而另半邊臉上僅以0.5%水楊酸處理。該草藥混合物包含1.5%馬齒莧萃取物、1.5%
掌葉大黃萃取物、1.5%油菊萃取物與0.5%黃芩根萃取物(黃芩苷)。
結果圖示於圖3，其顯示了僅以水楊酸處理，以及以上述之水楊酸與草藥混合物之結合物處理時，發炎性痤瘡病變減少之百分比。如圖3所示，單獨處理水楊酸僅減少約17%病變，而以草藥混合物連同水楊酸處理則減少32%發炎性病變。
Claims (20)
- 一種局部用配方，其包含馬齒莧(Portulaca oleracea)萃取物、掌葉大黃(Rheum palmatum)萃取物、油菊(Chrysanthemum indicum)萃取物與黃芩(Scutellaria baicalensis)根萃取物，或其活性成分黃芩苷(Baicalin)，結合去甲二氫癒創木酸(nordihydroguaiaretic acid)與齊墩果酸(oleanolic acid)。
- 如請求項1之局部用配方，係用於治療或預防痤瘡。
- 如請求項1之局部用配方，其更包含下列之一或多者：甘草酸二鉀(dipotassium glycyrrhizate)、洋甘菊(母菊屬)(Chamomilla recutita(matricaria))花萃取物，以及北美金縷梅(金縷梅)(Hamamelis virginiana(witch hazel)。
- 如請求項1之局部用配方，其更包含下列之一或多者：水楊酸、尿囊素(allantoin)，以及沒藥醇(α-bisabolol)。
- 如請求項1之局部用配方，其更包含下列之一或多者：高嶺土(kaolin)、氧化鋅、沙棘油(hippophae rhamnoides oil)、松蘿酸(usnic acid)、羥苯基丙醯胺基苯甲酸(hydroxyphenyl propamidobenzoic acid)、二氧化鈦。
- 如請求項1之局部用配方，其更包含下列之一或多者：咪唑啶基尿素(imidazolidinyl urea)、甲基氯異噻唑啉酮(methylchloroisothiazolinone)，以及甲基異噻唑啉酮(methylisothiazolinone)。
- 如請求項3與4中任一項之局部用配方，其中該配方具有 pH值範圍為約3.5-4.5。
- 如請求項5之局部用配方，該配方具有pH值範圍為約7.0-8.0。
- 一種局部用配方，其包含馬齒莧萃取物、無患子(Sapindus mukorossi)果萃取物，以及下列之至少一者：月桂醇聚醚硫酸銨(ammonium laureth sulfate)、椰油醯胺基丙基甜菜鹼(cocamidopropyl betaine)、椰油醯胺MEA(cocamide MEA)、椰油醯胺DEA(cocamide DEA)。
- 如請求項9之局部用配方，其係用於治療或預防痤瘡。
- 如請求項1至4中任一項之局部用配方，其中該水楊酸之含量範圍為0.5-2.0% w/w。
- 如請求項1之局部用配方，其中該配方為面霜或遮瑕膏。
- 如請求項9之局部用配方，其中該配方為潔淨凝膠。
- 如請求項12之局部用配方，其中該局部用配方為面霜時，該等草藥萃取物之結合濃度為至少0.9% w/w。
- 如請求項12之局部用配方，其中該局部用配方為遮瑕膏時，該等草藥萃取物之結合濃度為至少9.0% w/w。
- 如請求項12之局部用配方，當該局部用配方為面霜時，含有至少0.075%黃芩苷，而當該配方為遮瑕膏時，含有至少0.9%黃芩苷。
- 如請求項12之局部用配方，其中當該配方為遮瑕處理配方時，每一草藥萃取物之量為約3%。
- 如請求項12之局部用配方，其中當該配方為面霜配方時，每一草藥萃取物之量為約0.3%。
- 如請求項1之局部用配方，其中該配方提供有關皮脂分泌減少、皮膚油類吸收、抗發炎活性、抗菌活性、傷口癒合特性、抗氧化活性、皮膚刺激減少、配方之皮膚吸收，或任何其等結合之協同效用。
- 一種治療痤瘡之方法，其包含局部施用如請求項1之局部用配方於有需要之個體的步驟。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700568P | 2012-09-13 | 2012-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201417822A true TW201417822A (zh) | 2014-05-16 |
Family
ID=50278797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102133208A TW201417822A (zh) | 2012-09-13 | 2013-09-13 | 用於治療痤瘡的局部用組成物 |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW201417822A (zh) |
| WO (1) | WO2014041542A2 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110035797A (zh) * | 2016-11-13 | 2019-07-19 | 卡梅蒂丝有限公司 | 用于治疗痤疮的局部组合物 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104130230A (zh) * | 2014-06-30 | 2014-11-05 | 施佩蓓 | 一种黄芩素的生产方法 |
| TWI826395B (zh) * | 2017-10-19 | 2023-12-21 | 耶魯大學 | 以藥草萃取物及其組成物抑制雄性素受體 |
| WO2019135215A2 (en) * | 2018-01-02 | 2019-07-11 | Kamedis Ltd. | Herbal extracts for treatment of herpesvirus infections |
| CN113101244B (zh) * | 2020-01-13 | 2024-03-26 | 广州市科能化妆品科研有限公司 | 保湿乳和胶原酶抑制剂及其制备方法 |
| CN113925806B (zh) * | 2021-09-22 | 2022-12-06 | 广州环亚化妆品科技股份有限公司 | 一种水性液体眼影及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080281A1 (en) * | 1981-11-04 | 1983-06-01 | Wigglesworth Limited | Therapeutic use of allantoin-formaldehyde condensation products |
| MY124001A (en) * | 1999-04-23 | 2006-06-30 | E Excel Int | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
| FR2830195B1 (fr) * | 2001-10-03 | 2004-10-22 | Sederma Sa | Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique |
| CN1988879A (zh) * | 2004-07-23 | 2007-06-27 | 宝洁公司 | 包含类黄酮和维生素b3的护肤组合物 |
| US8147854B2 (en) * | 2005-06-21 | 2012-04-03 | Dow Corning Toray Company, Ltd. | Cosmetics comprising a modified organopolysiloxane |
| CN103533947A (zh) * | 2010-12-28 | 2014-01-22 | 卡梅迪斯有限公司 | 用于治疗和预防感染的植物提取物 |
-
2013
- 2013-09-12 WO PCT/IL2013/050772 patent/WO2014041542A2/en active Application Filing
- 2013-09-13 TW TW102133208A patent/TW201417822A/zh unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110035797A (zh) * | 2016-11-13 | 2019-07-19 | 卡梅蒂丝有限公司 | 用于治疗痤疮的局部组合物 |
| CN110035797B (zh) * | 2016-11-13 | 2022-08-23 | 卡梅蒂丝有限公司 | 用于治疗痤疮的具有益生元特性的协同草药组合物 |
| US11478522B2 (en) | 2016-11-13 | 2022-10-25 | Kamedis Ltd | Synergistic herbal compositions with prebiotic properties for treatment of acne |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014041542A3 (en) | 2015-07-23 |
| WO2014041542A2 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010257247B2 (en) | Mild leave-on skin care compositions | |
| EP3538219B1 (en) | Topical compositions for the treatment of acne | |
| CN107789308A (zh) | 一种温和控油祛痘精华 | |
| EP1940432B1 (en) | Anti-inflammatory compositions and methods of use | |
| TW201417822A (zh) | 用於治療痤瘡的局部用組成物 | |
| EP1074245A2 (en) | Composition using mineral salts for therapeutic treatment | |
| EP2711050A1 (de) | Zusammensetzung sowie kosmetische Zubereitung mit einer derartigen Zusammensetzung | |
| JPH09157172A (ja) | 皮膚外用剤及び湿疹薬 | |
| EP2566455B1 (en) | Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies | |
| BR102017003313B1 (pt) | Composição anticaspa e método para a prevenção, redução ou tratamento da caspa | |
| WO2013190542A2 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
| JP2000247893A (ja) | 抗菌剤、入浴剤組成物及び皮膚洗浄剤組成物 | |
| TW201412324A (zh) | 用於治療牛皮癬及皮脂溢出症之局部用組成物 | |
| JP2015081244A (ja) | ニキビ治療用医薬組成物 | |
| US20200030398A1 (en) | Skin care composition | |
| CN104287982B (zh) | 一种调节头皮油脂平衡的去屑组合物 | |
| DE60212842T2 (de) | Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten | |
| RU2671511C1 (ru) | Косметическая композиция для ухода за волосами и кожей головы (варианты) | |
| JP2000212057A (ja) | 化粧料組成物 | |
| CN110944649B (zh) | 鼠李糖及其衍生物作为抗真菌剂的用途 | |
| CN114306107A (zh) | 功效型皮肤用产品及其制备方法 | |
| CN111840428A (zh) | 一种抗炎杀菌舒缓祛痘的外用喷雾 | |
| KR101548254B1 (ko) | 유황, 명반 및 식초를 유효성분으로 포함하는 피부 질환 치료용 조성물 | |
| WO2019175902A1 (en) | A topical preparation for various skin ailments | |
| KR20190132197A (ko) | 여드름이 생기기 쉬운 피부의 치료 및 예방에 사용하기 위한 화장품 조성물 |